European Commission Approves BLINCYTO(R) (blinatumomab) In Patients With Philadelphia Chromosome Negative Minimal Residual Disease-Positive B-cell Precursor Acute Lymphoblastic Leukemia

BLINCYTO is the First and Only Therapy for Minimal Residual Disease Approved in the European Union Approval Based on Data From the Phase 2 BLAST Study, the Largest Prospective Trial in Minimal Residual Disease-Positive Acute Lymphoblastic Leukemia TH... Biopharmaceuticals, Oncology, Regulatory Amgen, BLINCYTO, blinatumomab, Acute Lymphoblastic Leukemia
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news